Pharmafile Logo

Fighting talk

April 2, 2015 | Cancer 

One thing that grasps my interest is how society has adopted military style language when talking about cancer

Treatments are described as “defending” or “protecting” whilst cancer patients themselves are “fighters” who “battle” to “beat” the disease. These abstract metaphors of war are used in an attempt to articulate that cancer is a very emotional experience for all involved.

This terminology is intriguing to me, as whilst widely recognised as persuasive, it is also considered controversial.  War-like analogies suggest that there will be a “winner”, “loser”, and a “battlefield”. Sadly there are hundreds of types of cancer, and short of resection, there is no definitive cure for any of them. Many patients inevitably end up the “loser” as they endure a “battle” against symptoms of the disease, and the side effects of therapy – which all too often only gains a few more months PFS before the “fight” is “lost”. Perhaps more poignantly, their own bodies are the “battlefield” where this all takes place. I have to ask myself, how do progressed metastatic patients feel anything other than failure when we talk about the disease in this way? 
When I’ve personally conducted interviews with medical professionals and patients alike, I hear time and time again their aversion to this style of language. Oncologists have even told me that in medical school they were taught to actively avoid using this vocabulary, and as a result they are unresponsive to any type of marketing materials delivered in this style.

So why, when companies are spending so much time and resources into researching effective messaging, are we continuing to use language that knowingly disengages the target audience? As researchers we know that it’s imperative to ensure that brand messaging speaks directly, and appropriately, to our target audience – and sometimes when conducting research that’s not always just about what the respondent says but rather, how they say it. By including some extra language profiling questions and completing an extra step of analysis when conducting market research, we can determine what segments are likely to exhibit a particular trend of language compared to another segment. The value to this insight is that our language is usually indicative of our behaviour; thus providing an extra layer of understanding into the minds of customers in terms of how they might behave in a particular context, which can inform both communications and sales materials.

Knowing what language ‘works’ for different customers can bring to life the other key factors that are relevant to each audience segment – which not only increases buy-in at implementation but also tailors the communication for optimal outcomes.

With approximately 100 projects conducted in oncology within the last 2 years, it’s the single largest therapeutic area studied at the Research Partnership, and it is clear to see that advances in detecting, diagnosing, and treating cancer have evolved – and are continuing to evolve at a significant rate. Perhaps it’s time we also evolve the way we talk about it, ensuring that we speak in language relevant to the target audience, avoid the “fighting talk” clichés and start using unique positive terminology to talk about “life beyond cancer”?

Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.Find out more here: http://bit.ly/1IxUzjW

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

EphMRA Annual Conference 2017

Visit us on stand number 14

Richard Head nominated for EphMRA Award

We are delighted to announce that Research Partnership’s Director Richard Head has been nominated for The EphMRA President’s Award for Contribution to Pharmaceutical Market Research.According to EphMRA, Richard has been...

Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report

Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

EULAR Annual European Congress of Rheumatology 2017

Join us at EULAR Congress 2017 in Madrid, 14-17 June

PEGASUS UNVEILS NEW BRAND IDENTITY AS IT CELEBRATES A YEAR AS PART OF ASHFIELD

Pegasus, an Ashfield company, part of UDG Healthcare plc, has unveiled a new brand identity signaling its successful integration with the global business, a year on from acquisition. Conceived by...

20 questions: Round 2

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What do you love about your job?"Watch the video: http://bit.ly/2qA1oP9

Taking an integrated approach to research

Director Melinda Shorr and Associate Director Steven Helm discuss the benefits of integrated research techniques.Watch the video: http://bit.ly/2qF0qO2

Online Community Research

What to consider when running an online research community?

Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch

Helen Parfitt has joined Research Partnership as Head of Therapy Watch at the company’s global head office in London. Therapy Watch is a ‘real-time’ syndicated global market tracking tool that...

Research Partnership is expanding its US capabilities with new offices opening in San Francisco and New York

Research Partnership is today expanding its US operations across both the West and East Coast. Director Tom Winter has relocated from London and is today opening a new office in...